---
title: "BioKangtai and AstraZeneca sign a license termination agreement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259474198.md"
description: "BioKangtai and AstraZeneca signed a termination agreement to end the research, production, and commercialization cooperation of the ChAdOx1 adenovirus vector COVID-19 vaccine. Due to changes in the market environment and the impact of COVID-19 vaccine variants, both parties decided to terminate the original licensing agreement after friendly consultations, with all rights and obligations ending from the effective date of the new agreement"
datetime: "2025-09-30T08:12:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259474198.md)
  - [en](https://longbridge.com/en/news/259474198.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259474198.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/259474198.md) | [繁體中文](https://longbridge.com/zh-HK/news/259474198.md)


# BioKangtai and AstraZeneca sign a license termination agreement

According to the Zhitong Finance APP, BioKangtai (300601.SZ) announced that on August 20, 2020, the company signed a License Agreement with AstraZeneca UK Limited (hereinafter referred to as "AstraZeneca"), granting AstraZeneca exclusive authorization for the company to conduct research and development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine (hereinafter referred to as "licensed product") within the People's Republic of China (excluding Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan).

In light of significant changes in the domestic and international COVID-19 vaccine strains and market environment, both parties have decided to terminate the cooperation on the research and development, production, and commercialization of the licensed product (ChAdOx1 adenovirus vector COVID-19 vaccine) through friendly consultation. Recently, they signed a License Termination Agreement, and all rights and obligations under the original License Agreement will terminate upon the effective date of the License Termination Agreement signed by both parties

### Related Stocks

- [BioKangtai (300601.CN)](https://longbridge.com/en/quote/300601.CN.md)

## Related News & Research

- [AIM Vaccine Plans Beijing A-Share Listing and New Domestic Share Issuance](https://longbridge.com/en/news/281055261.md)
- [Key facts: Dupixent Japan approval; Sarclisa CHMP nod; IL‑33 COPD fails](https://longbridge.com/en/news/280859187.md)
- [Precise Biometrics Calls EGM to Approve Merger With Fingerprint Cards](https://longbridge.com/en/news/281003945.md)
- [08:41 ETGELITA Champions "BE ACTIVE!" at SupplySide Connect with Innovative Collagen Solutions and Delivery Formats](https://longbridge.com/en/news/281189481.md)
- [Asia remains world’s most wallet led region as A2A payments accelerate – Worldpay](https://longbridge.com/en/news/281303588.md)